Endemic mycoses: a treatment update

J Antimicrob Chemother. 1999 Mar;43(3):321-31. doi: 10.1093/jac/43.3.321.


Endemic mycoses remain a major public health problem in several countries and they are becoming increasingly frequent with the spread of HIV infection. Amphotericin B remains the drug of choice during the acute stage of life-threatening endemic mycoses occurring in both immunocompetent and immunocompromised hosts. Ketoconazole is effective in non-AIDS patients with non-life-threatening histoplasmosis, blastomycosis, or paracoccidioidomycosis. Itraconazole is the treatment of choice for non-life-threatening Histoplasma capsulatum or Blastomyces dermatitidis infections occurring in immunocompetent individuals and is the most efficient secondary prophylaxis of histoplasmosis in AIDS patients. Itraconazole is also effective in lymphocutaneous and visceral sporotrichosis, in paracoccidioidomycosis, for Penicillum marneffei infection, and is an alternative to amphotericin B for Histoplasma duboisii infection. Coccidioidomycosis may be effectively treated with prolonged and sometimes life-long itraconazole or fluconazole therapy. Fluconazole has relatively poor efficacy against histoplasmosis, blastomycosis and sporotrichosis. New antifungal agents have been tested in vitro or in animal models and may soon be evaluated in clinical trials.

Publication types

  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • Amphotericin B / therapeutic use
  • Blastomycosis / drug therapy
  • Coccidioidomycosis / drug therapy
  • Histoplasmosis / drug therapy
  • Humans
  • Mycoses / drug therapy*
  • Paracoccidioidomycosis / drug therapy
  • Sporotrichosis / drug therapy


  • Amphotericin B